GLP-1s and Gastroparesis: Where Normal Side Effects End

At a glance

• Track symptom timing, food and fluid intake, and recent dose changes.
• Persistent severe abdominal pain or an inability to keep fluids down needs prompt assessment.
• A delayed-emptying effect does not itself establish a diagnosis of gastroparesis.

The question this guide answers

Nausea during treatment does not establish gastroparesis. Persistent symptoms require an assessment, and the product labels advise against use in severe gastroparesis.

Sources: Wegovy prescribing informationZepbound prescribing informationFoundayo prescribing information

Describe the symptom instead of guessing the cause

Record what happens, when it began, whether there was a dose change and whether eating, drinking or bowel movements are affected. Other medicines and illnesses can cause similar symptoms.

Smaller tolerable meals and avoiding foods that worsen symptoms may help with mild nausea. A clinician should decide whether treatment needs to be paused or changed rather than expecting someone to endure escalating symptoms.

Sources: Wegovy prescribing informationZepbound prescribing informationFoundayo prescribing information

Where self-management ends

Severe or persistent abdominal pain, repeated vomiting, fainting or signs of dehydration can require urgent medical care. Product labels include warnings for pancreatitis, gallbladder problems, volume depletion and severe gastrointestinal reactions.

Do not diagnose gastroparesis from nausea alone. It requires clinical evaluation. The labels advise against use in severe gastroparesis, and preexisting stomach problems belong in the initial assessment.

Sources: Wegovy prescribing informationZepbound prescribing informationFoundayo prescribing information

Make the contact pathway clear before starting

Ask who responds to symptoms, how quickly clinical questions are reviewed and what to do after hours. A fulfillment or customer-support team is not necessarily the clinician who can change the prescription.

Do not increase a dose to follow a fixed calendar when tolerance is poor. A longer interruption also requires a discussion of safe restarting.

Sources: Wegovy prescribing informationZepbound prescribing informationFoundayo prescribing information

Sources and review boundaries

Source check dates are listed below. First-party pages support descriptions of a service’s public offer; medical references support the educational context. They do not establish an independent clinical audit of a provider. This is general education, not personal medical advice; no named licensed clinical reviewer has reviewed this article.

1. Wegovy prescribing informationMedical or regulatory source · Source reviewed · 2026-10-02
2. Zepbound prescribing informationMedical or regulatory source · Source reviewed · 2026-10-02
3. Foundayo prescribing informationMedical or regulatory source · Source reviewed · 2026-10-02